Ovid Therapeutics (OVID) Total Current Liabilities (2016 - 2026)

Ovid Therapeutics has reported Total Current Liabilities for 11 years, with the latest figure at $15.7 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities rose 69.21% year-over-year to $15.7 million; the trailing twelve-month figure through Mar 2026 stood at $15.7 million (up 69.21% YoY), and the FY2025 full-year result was $8.3 million, down 21.23% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $15.7 million, up from $8.3 million in the prior quarter.
• The five-year high for Total Current Liabilities was $15.7 million in Q1 2026, with the low at $6.7 million in Q1 2023.
• Historically, Total Current Liabilities has averaged $9.9 million across 5 years, with a median of $9.1 million in 2025.
• Annual changes were most pronounced in 2022 — Total Current Liabilities sank 52.75% — and 2026, when it surged 69.21%.
• Ovid Therapeutics' Total Current Liabilities stood at $7.0 million in 2022, then jumped by 64.1% to $11.5 million in 2023, then declined by 8.29% to $10.5 million in 2024, then retreated by 21.23% to $8.3 million in 2025, then soared by 90.01% to $15.7 million in 2026.
• The last three Total Current Liabilities figures came in at $15.7 million (Q1 2026), $8.3 million (Q4 2025), and $6.8 million (Q3 2025), per Business Quant data.